Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWDNOK)

Drug Name

REVERSINE Drug Info

Synonyms

Reversine; 656820-32-5; 2-(4-Morpholinoanilino)-6-cyclohexylaminopurine; UNII-Z499CLJ023; CHEMBL188343; CHEBI:70723; ZFLJHSQHILSNCM-UHFFFAOYSA-N; Z499CLJ023; N~6~-Cyclohexyl-N~2~-(4-Morpholin-4-Ylphenyl)-9h-Purine-2,6-Diamine; IN1127; 9H-Purine-2,6-diamine,N6-cyclohexyl-N2-[4-(4-morpholinyl)phenyl]-; C21H27N7O; N6-cyclohexyl-N2-(4-morpholinophenyl)-7H-purine-2,6-diamine; N(6)-cyclohexyl-N(2)-[4-(morpholin-4-yl)phenyl]-9H-purine-2,6-diamine; 2vgo; Reversine(HPLC); AD5; AC1L4OI2; AC1Q4YB4; MLS006010275; SCHEMBL1800790

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 210332
ChEBI ID: CHEBI:70723
CAS Number: CAS 656820-32-5
TTD Drug ID: DMWDNOK

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Discontinued Drug(s)

Investigative Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting ERK activator kinase 1 (MEK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selumetinib	DMC7W6R	Neurofibromatosis type 1	LD2D.10	Phase 3	[3]
Diamidothiazole derivative 1	DM02V5Q	N. A.	N. A.	Patented	[4]
Pyridic ketone derivative 1	DM3GU7K	N. A.	N. A.	Patented	[5]
RDEA-436	DM0ILRU	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[6]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[7]
DEBROMOHYMENIALDISINE	DMDLER8	Discovery agent	N.A.	Investigative	[8]
OROIDIN	DMA2DQT	Discovery agent	N.A.	Investigative	[8]
PD98059	DMZC90M	Cardiac arrest	MC82	Investigative	[9]
4,5-Dibromo-1H-pyrrole-2-carboxylic acid amide	DMDM9UV	Discovery agent	N.A.	Investigative	[8]
5-phenylamino-4-cyano-3-hydroxy-isothiazole	DMX6R0H	Discovery agent	N.A.	Investigative	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Adenosine A3 receptor (ADORA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IB-MECA	DM9G5XD	Psoriasis vulgaris	EA90	Phase 3	[11]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[12]
NITD609	DMQHBSX	Malaria	1F40-1F45	Phase 2	[13]
CF102	DMP56WJ	Hepatocellular carcinoma	2C12.02	Phase 2	[14]
SCH-442416	DMQ2K1V	N. A.	N. A.	Phase 1	[15]
AST-004	DM5WMG7	Stroke	8B20	Phase 1	[16]
BEMESETRON	DMSPJX9	N. A.	N. A.	Discontinued in Phase 3	[17]
BAY 60-6583	DMTEJV1	Myocardial ischemia	BA6Z	Preclinical	[18]
CF602	DM0ULO2	Inflammation	1A00-CA43.1	Preclinical	[14]
CF502	DMQSJ20	Inflammation	1A00-CA43.1	Preclinical	[14]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosine A3 receptor (ADORA3)	TTJFY5U	AA3R_HUMAN	Inhibitor	[1]
ERK activator kinase 1 (MEK1)	TTIDAPM	MP2K1_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8.
2	Reversine increases the plasticity of lineage-committed mammalian cells. Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10482-7.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
5	MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906.
6	Clinical pipeline report, company report or official report of MedKoo Biosciences.
7	Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
8	Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). J Med Chem. 2002 Jan 17;45(2):529-32.
9	The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis. Melanoma Res. 2001 Feb;11(1):11-9.
10	Discovery of 3-hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles as potent MEK1 inhibitors. Bioorg Med Chem Lett. 2006 Aug 1;16(15):3975-80.
11	A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. 1993 Dec 20;336(1):57-60.
12	2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
13	Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
14	2011 Pipeline of Can-Fite BioPharm.
15	Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5690-4.
16	Adenosine A1R/A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 Reduces Brain Infarction in a Nonhuman Primate Model of Stroke. Stroke. 2022 Jan;53(1):238-248.
17	2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
18	Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol. 2007 Sep;43(3):262-71.